| Literature DB >> 27661612 |
Yan Fu1, Andreas L Chryssafidis1, John A Browne2, Jack O'Sullivan1, Paul A McGettigan2, Grace Mulcahy1,3.
Abstract
BACKGROUND: Fasciola hepatica is not only responsible for major economic losses in livestock farming, but is also a major food-borne zoonotic agent, with 180 million people being at risk of infection worldwide. This parasite is sophisticated in manipulating the hosts' immune system to benefit its own survival. A better understanding of the mechanisms underpinning this immunomodulation is crucial for the development of control strategies such as vaccines. METHODOLOGY/PRINCIPALEntities:
Year: 2016 PMID: 27661612 PMCID: PMC5035020 DOI: 10.1371/journal.pntd.0005015
Source DB: PubMed Journal: PLoS Negl Trop Dis ISSN: 1935-2727
Fig 1Timeline of the experimental vaccination trial.
Experimental procedures were carried out under license from the Health Products Regulatory Authority (Project Authorization Number: AE18982/P010) and after ethical review by the University College Dublin (UCD) Animal Ethics Committee.
List of ID numbers for genes mentioned in the text.
| Gene Name | ESEMBL Ovine Gene ID |
|---|---|
| A2M | ENSOARG00000000950 |
| ACTB | ENSOARG00000003021 |
| ATP5G1/ATP synthase | ENSOARG00000006653 |
| B2M | ENSOARG00000003782 |
| CASP3 | ENSOARG00000007472 |
| CCL2 | ENSOARG00000009627 |
| CCR2 | ENSOARG00000014236 |
| CD28 | ENSOARG00000018277 |
| CD40 | ENSOARG00000008369 |
| COL1A1 | ENSOARG00000004871 |
| CYCS | ENSOARG00000025169 |
| MAPK1/ERK1/2 | ENSOARG00000015529 |
| FAS | ENSOARG00000014866 |
| GAPDH | ENSOARG00000007894 |
| CSF2/GM-CSF | ENSOARG00000015430 |
| GUSB | ENSOARG00000001578 |
| HSPB1/HSP27 | ENSOARG00000013748 |
| IFNG | ENSOARG00000001958 |
| IFNGR1 | ENSOARG00000000510 |
| IL10 | ENSOARG00000006292 |
| IL10RA | ENSOARG00000007625 |
| IL15 | ENSOARG00000012119 |
| IL17F | ENSOARG00000014066 |
| IL17RC | ENSOARG00000005521 |
| IL18 | ENSOARG00000016193 |
| IL23A | ENSOARG00000009246 |
| IL23R | ENSOARG00000011083 |
| IL27 | ENSOARG00000003180 |
| IL4 | ENSOARG00000014896 |
| IL6 | ENSOARG00000012021 |
| NOS2/iNOS | ENSOARG00000016744 |
| JAK2 | ENSOARG00000013480 |
| MAP2K4/MKK4 | ENSOARG00000015404 |
| novel gene (CXCL5) | ENSOARG00000014592 |
| novel gene (TNFRSF10A/B) | ENSOARG00000017294 |
| SERPINE3/PAI-1 | ENSOARG00000008852 |
| PGK1 | ENSOARG00000018803 |
| PPARA/PPAR-α | ENSOARG00000019427 |
| RORC | ENSOARG00000021060 |
| RPL19 | ENSOARG00000010582 |
| SKI | ENSOARG00000000230 |
| SMAD3 | ENSOARG00000018276 |
| SMAD4 | ENSOARG00000004662 |
| SMAD7 | ENSOARG00000003809 |
| STAT1 | ENSOARG00000013903 |
| TBP | ENSOARG00000005142 |
| TGFΒ1 | ENSOARG00000007468 |
| TLR1 | ENSOARG00000000538 |
| TLR10 | ENSOARG00000000520 |
| TLR4 | ENSOARG00000005792 |
| TLR5 | ENSOARG00000005017 |
| TLR6 | ENSOARG00000000552 |
| TLR7 | ENSOARG00000011288 |
| TNF | ENSOARG00000008333 |
| TNFRSF1A | ENSOARG00000025177 |
| TNFRSF1B | ENSOARG00000017205 |
| TNFRSF21 | ENSOARG00000011638 |
| TNFRSF25 | ENSOARG00000012170 |
| TNFSF12 | ENSOARG00000000747 |
Fig 2PCA and BGA analysis.
(A) Principal component analysis (PCA). The 32 samples are projected onto the 2D plane such that they spread out in the two directions that explain most of the differences. The x-axis, so called the first principal component (PC1), is the direction that separates the samples the most. The y-axis, so called the second principal component (PC2), is an unrelated direction (it must be orthogonal to the first direction) that separates the data the second most. The percentage value in the axis label refers to the percent of the total variance that is contained in the direction. Each sample is represented as time points (T0-T3) followed by its animal ID. For example, T3V3 represents the transcriptome sample from vaccinated lamb V3 at time point 3 (14 wpi). (B) The between groups analysis (BGA) plot based on overall gene expression profiles of different groups in response to F. hepatica infection over the period of time. V and C represent vaccinated and control group respectively and their time point (0–3) is separated by a dot in each group.
Fig 3Venn diagram showing the numbers of DEGS identified from T2vsT1 and T3vsT2.
Overlap comparison of DEGS from two comparisons (T2vsT1 and T3vsT2) according to direction of expression. Sets of up- / down- regulated genes of T2vsT1 are represented in blue and yellow, up- / down- regulated genes of T3vsT2 in pink and green.
Top 10 overlapped IPA canonical pathways in T2vsT1 and T3vsT2 respectively, ranked by overlap p-value.
| Pathway Name | -log(p-value) | Ratio | z-score |
|---|---|---|---|
| Production of Nitric Oxide and Reactive Oxygen Species in Macrophages | 5.82 | 0.33 | -1.291 |
| Germ Cell-Sertoli Cell Junction Signaling | 5.78 | 0.34 | NaN |
| IL-6 Signaling | 5.55 | 0.37 | -1.982 |
| phagosome formation | 5.28 | 0.37 | NaN |
| Role of | 5.09 | 0.45 | NaN |
| Xenobiotic Metabolism Signaling | 5.03 | 0.30 | NaN |
| Role of Macrophages, Fibroblasts and Endothelial Cells in Rheumatoid Arthritis | 5.01 | 0.29 | NaN |
| Death Receptor Signaling | 4.93 | 0.38 | 1.521 |
| TREM1 Signaling | 4.67 | 0.40 | -2.921 |
| Toll-like Receptor Signaling | 4.47 | 0.39 | -1.091 |
| Calcium Signaling | 3.15 | 0.16 | -0.426 |
| Role of CHK Proteins in Cell Cycle Checkpoint Control | 2.81 | 0.22 | -0.302 |
| Antigen Presentation Pathway | 2.57 | 0.24 | NaN |
| Unfolded protein response | 2.37 | 0.20 | NaN |
| Role of BRCA1 in DNA Damage Response | 2.34 | 0.18 | -0.632 |
| Protein Ubiquitination Pathway | 2.29 | 0.13 | NaN |
| GDNF Family Ligand-Receptor Interactions | 2.29 | 0.18 | 1.941 |
| Endoplasmic Reticulum Stress Pathway | 2.23 | 0.29 | NaN |
| p53 Signaling | 2.18 | 0.16 | -0.775 |
| TR/RXR Activation | 2.07 | 0.16 | NaN |
*The overlap p-value indicates the probability of association of molecules from our dataset with the canonical pathway by random chance alone using Fisher’s exact test.
** In a given pathway, the ratio is calculated as number of genes in our dataset that meet the cutoff criteria, divided by the total number of genes involved in that pathway.
***The Z-score is used to indicate an overall activity status of the pathway. Z < 0 indicates a prediction of an overall decrease in activity while Z > 0 predicts an overall increase in the activity. NaN indicates pathways that are currently ineligible for a prediction.
Fig 4TGF-β signaling pathway.
The TGFB signaling pathway is represented with gene expression (log2 fold-change) values overlaid. Red shading indicates increased expression in PBMCs at T2 compared to T1. Green shading indicates decreased expression in PBMC at T2 compared to T1. Color intensity indicates expression level. White and grey shading indicates no significantly differential expression, and filtered out due to low expression respectively.
Fig 5Production of nitric oxide in macrophages.
This pathway is represented with gene expression (log2 fold-change) values overlaid. Red shading indicates increased expression in PBMCs at T2 compared to T1. Green shading indicates decreased expression in PBMCs at T2 compared to T1. Color intensity indicates expression level. White and grey shading indicates not significantly differentially expressed and filtered out due to low expression, respectively.
The selected gene expression level in several pathways of interest.
| Pathway Name | Symbol | Description | Exp. Ratio T2/T1 | adj. | Exp. Ratio T3/T2 | adj. |
|---|---|---|---|---|---|---|
| 2.231 | 0.023 | - | - | |||
| collagen, type I, alpha 1 | 14.607 | 0.02 | 10.068 | 0.002 | ||
| SMAD family member 3 | 3.775 | 0.005 | - | - | ||
| 4.242 | 1.82E-04 | 0.478 | 0.019 | |||
| SMAD family member 7 | 22.865 | 9.33E-06 | - | - | ||
| 47.729 | 0.002 | - | - | |||
| Production of nitric oxide in Macrophages | nitric oxide synthase 2, inducible | 5.64E-09 | 4.17E-06 | - | - | |
| 0.064 | 0.007 | 2.304 | 0.02 | |||
| Interleukin-4 | 63.181 | 0.001 | - | - | ||
| 0.393 | 0.035 | - | - | |||
| Janus kinase 2 | 0.217 | 0.002 | - | - | ||
| Toll-like receptor signaling | 0.005 | 2.33E-06 | 5.057 | 0.001 | ||
| 3.664 | 0.033 | 0.363 | 0.006 | |||
| 0.036 | 0.014 | 105.282 | 0.014 | |||
| 0.017 | 9.36E-06 | - | - | |||
| 0.045 | 8.55E-05 | 3.136 | 0.012 | |||
| 0.002 | 9.93E-06 | - | - | |||
| Death receptor signaling & Apoptosis signaling | 9.386 | 0.023 | - | - | ||
| 4.515 | 0.029 | - | - | |||
| tumor necrosis factor receptor 2, TNFR2 | 4.461 | 0.001 | - | - | ||
| tumor necrosis factor (ligand) superfamily, member 12, APO3L | 16.755 | 0.055 | - | - | ||
| tumor necrosis factor receptor superfamily, member 25, death receptor 3, DR3 | 27.218 | 9.94E-05 | - | - | ||
| Orthologue of human tumor necrosis factor receptor superfamily, member 10a/b, death receptor 4/5, DR4/5 | 5.83 | 0.025 | - | - | ||
| tumor necrosis factor receptor superfamily, member 21, death receptor 6, DR6 | 6.005 | 0.021 | - | - | ||
| 0.317 | 0.009 | - | - | |||
| Cytochrome c | 2.776 | 0.028 | 9.148 | 0.011 | ||
| caspase 3, apoptosis-related cysteine peptidase | - | - | 4.545 | 0.001 | ||
| T helper cell differentiation & | RAR-related orphan receptor C | 0.073 | 0.005 | - | - | |
| 0.398 | 0.031 | - | - | |||
| interleukin 23 receptor | 3.60E-04 | 6.33E-05 | - | - | ||
| interleukin 17F | 0.017 | 0.002 | - | - | ||
| interleukin 17 receptor C | 0.01 | 3.38E-04 | 2.074 | 0.038 | ||
| Orthologues of human chemokine (C-X-C motif) ligand 5, CXCL5 | 0.005 | 5.02E-05 | - | - | ||
| chemokine (C-C motif) ligand 2 | 0.012 | 0.001 | - | - | ||
| chemokine (C-C motif) receptor 2 | 0.048 | 0.002 | - | - |
Predicted upstream regulators of interest at acute stage of F. hepatica infection (T2vsT1), ranked by overlap p-value.
| Upstream Regulator | Exp Log Ratio | Predicted Activation State | Activation z-score | p-value of overlap | No. of targeted genes in dataset |
|---|---|---|---|---|---|
| -3.959 | Inhibited | -3.696 | 1.71E-19 | 347 | |
| 3.23 | Inhibited | -3.929 | 3.36E-19 | 413 | |
| -2.99 | 0.423 | 3.84E-16 | 125 | ||
| Activated | 2.502 | 9.26E-13 | 77 | ||
| IL13 | 0.857 | 2.64E-12 | 122 | ||
| -7.404 | -1.427 | 2.28E-11 | 313 | ||
| IL15 | -3.363 | Inhibited | -2.226 | 1.32E-10 | 114 |
| Activated | 2.105 | 5.61E-08 | 55 | ||
| 1.873 | Inhibited | -3.773 | 6.60E-08 | 92 | |
| 4.515 | 0.407 | 2.31E-07 | 46 | ||
| 2.742 | Inhibited | -3.047 | 3.42E-07 | 67 | |
| 2.007 | Activated | 2.28 | 3.64E-07 | 96 | |
| 2.592 | Activated | 2.881 | 7.15E-06 | 84 | |
| Inhibited | -5.102 | 7.25E-06 | 70 | ||
| -5.513 | Inhibited | -3.512 | 1.27E-04 | 42 | |
| Inhibited | -2.961 | 1.96E-04 | 44 | ||
| Inhibited | -3.581 | 2.11E-04 | 56 | ||
| -5.848 | Inhibited | -3.346 | 4.37E-04 | 13 | |
| -7.669 | Inhibited | -2.135 | 5.86E-04 | 10 | |
| -4.803 | Inhibited | -2.407 | 3.02E-03 | 14 | |
| Inhibited | -3.698 | 3.10E-03 | 60 | ||
| Inhibited | -2.412 | 6.32E-03 | 6 | ||
| -4.486 | Inhibited | -2.697 | 1.59E-02 | 30 | |
| 4.067 | Inhibited | -3.743 | 2.12E-02 | 23 | |
| 2.085 | 1.091 | 3.16E-02 | 48 |
*The z-score is used to infer whether an upstream regulator is likely to be activated (z > 2) or inhibited (z < -2). It is calculated from the proportions of downstream genes which are consistent with an expected expression direction based on the known interaction between the regulator and the genes present in the IPA’s database.
**The overlap p-value indicates whether there is a statistically significant overlap between the dataset genes and the genes that are known to be regulated by a transcriptional regulator using Fisher’s exact test.
Fig 6Upstream regulator analysis predicts IL18 and IL12 (complex) to be inhibited in PBMC in early infection with F. hepatica.
Downstream target genes are highlighted as upregulated (red) or downregulated (green) at T2vsT1, in the symbols at the edge of the circle, with color intensity increasing with degree of fold change. The activation state of predicted upstream regulators, IL12 (complex) and IL18, is indicated as inhibited (sold blue area within the circle). Arrowheads at the end of interactions (dotted lines) indicate activation, while bars indicate inhibitory effects. The color of lines represent predicted relationships based on gene expression, including orange (activation), blue (inhibition), yellow (findings inconsistent with state of downstream molecule) and grey (effect not predicted).